Shopping Cart
- Remove All
- Your shopping cart is currently empty
WNK-IN-B is an inhibitor of Wnk signalling. WNK-IN-B is a cell-permeable diaminoacridine derivative that targets the CCT domain of SPAK and OSR1 via reversible binding. WNK-IN-B selectively suppress hypotonic shock-induced WNK signaling pathway activation in mpkDCT and MOVAS (100 µM) cultures without affecting p38 MAPK phosphorylation.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,470 | 6-8 weeks | |
50 mg | $1,910 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | WNK-IN-B is an inhibitor of Wnk signalling. WNK-IN-B is a cell-permeable diaminoacridine derivative that targets the CCT domain of SPAK and OSR1 via reversible binding. WNK-IN-B selectively suppress hypotonic shock-induced WNK signaling pathway activation |
Targets&IC50 | WNK1:34.4 μM (IC50), WNK4:16 μM (IC50) |
Alias | WNK-IN-B, WNK IN B, Compound B |
Molecular Weight | 333.38 |
Formula | C20H19N3O2 |
Cas No. | 332922-63-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.